Danon Disease Gene Therapy Study Moves Forward After FDA Review

A clinical study of an investigational gene therapy (RP-A501) for Danon disease is moving forward after the U.S. Food and Drug Administration (FDA) reviewed early safety information.

The gene therapy is being studied as a potential treatment for people with Danon disease, a rare genetic condition that can seriously affect the heart.

The gene therapy being studied, RP-A501, is designed to deliver a working copy of the gene to heart cells, with the goal of helping them produce a protein affected by Danon disease.

As more and more gene therapies are studied and approved by the FDA, they open up many new options for people with rare genetic diseases.

Early Safety Results

The safety of patients is always a top priority. The FDA reviewed information from the first three patients treated with this investigational gene therapy and with an updated plan for treating them. All three patients were followed up by the study team for at least four weeks and were discharged from the hospital by 1-2 weeks following gene therapy infusion.

So far, none of the three patients have shown signs of two serious complications that researchers were monitoring:

• Thrombotic microangiopathy, a condition that can cause problems with small blood vessels and blood clots.
• Capillary leak syndrome, a condition in which fluid can leak from blood vessels into surrounding tissues.

These early findings are based on three participants with limited follow-up. Safety monitoring is ongoing.

After reviewing the available safety information, the FDA confirmed that the study can continue using the updated dosing plan for the gene therapy being studied.

More Patients Will Join the Study

The main study is expected to include 12 male patients who receive the updated dose of RP-A501.

The first three patients treated with the updated dose already count toward those 12 patients. This means that researchers need to enroll and treat nine more patients.

The study is hoping to be completed by mid-2027.

What Will Researchers Look For?

Researchers will check how participants respond to the treatment 12 months after receiving the study’s gene therapy, researchers will assess whether LAMP2 protein is present in heart tissue and whether excess heart muscle mass has decreased. If these specific measures are achieved, they could potentially support a faster approval from the FDA.

What Comes Next?

The FDA's review allows the clinical study to continue. With three patients already counted in the main study group, researchers are working towards enrolling the remaining nine patients.

The study's progress will provide more information about the safety of RP-A501 and whether the treatment may help address some of the heart problems associated with Danon disease.

It is important to remember that RP-A501 is still an investigational treatment. The study is ongoing, and researchers will need to collect and analyze additional data before its potential benefits and risks are fully understood.

If you or a family member has Danon disease and would like to learn more about the study, contact Know Rare here. The study team can explain the eligibility requirements and determine whether participation may be appropriate.